Archive for the ‘Gene Therapy Research’ Category

WASHINGTON--(BUSINESS WIRE)--

Today, the Genetics Policy Institute (GPI) announced the opening of a new, GPI National Affairs Office in Washington, D.C.

Recent years have seen GPIs involvement with policy and regulatory issues impacting the translation of stem cells and other advanced technologies into medicine steadily increase, necessitating the establishment of a new, permanent office location in the nations capital.

This new location will also give GPI the opportunity to begin hosting an array of high-level workshops, seminars, and events aimed at removing roadblocks to innovative bio-medical solutions found within the fields of stem cell research and regenerative medicine.

Said GPIs Executive Director, Bernard Siegel of the need for advocacy driven workshops and related events, While many other countries are establishing funded, national programs or strategies to advance cell therapies and regenerative medicine, the US lags.

He added that time is of the essence as patients are facing the crushing burden of chronic disease and immense human suffering. To fulfill the curative promise in years, rather than decades, Washington must declare regenerative medicine a national priority and immediately establish coordination between federal agencies. We need a consensus strategy that includes all necessary funding.

Being at the intersection of research, medicine, law and patient advocacy, GPI boasts a track record of bringing stakeholders together with the aim of delivering on the promise of stem cells and regenerative medicine.

About the Genetics Policy Institute (GPI): GPI is a 501(c)(3) nonprofit corporation with the mission to promote stem cell research and its application in medicine to develop therapeutics and cures for many otherwise intractable diseases and disorders. GPI pursues this mission through production of its flagship annual World Stem Cell Summit, publication of the World Stem Cell Report, the online newsletter 360 Weekly, special projects, speaking engagements, educational initiatives, and strategic collaborations.

GPI maintains offices in Palm Beach, Florida; Palo Alto, California and Washington, D.C. For more information, visit http://www.genpol.org.

Please direct all media inquires to GPI Associate Director, Alan Fernandez at Genetics Policy Institute, 701 8th Street NW, Suite 400, Washington, DC, telephone 888-238-1427 or email alan@genpol.org.

More:
Genetics Policy Institute Opens Washington, D.C. Office

SALT LAKE CITY, May 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) today announced results for its third fiscal quarter and nine months ended March 31, 2013. Revenue for the third fiscal quarter increased 21 percent over the same period in the prior year to $156.5 million. Third fiscal quarter earnings per diluted share were $0.46, an increase of 34 percent over the same period of the prior year.

"I am pleased with not only the solid revenue growth across all of our business segments during the third quarter but also the Company's ability to drive financial leverage as we continue to invest in our extensive product pipeline," said Peter D. Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We are very optimistic regarding the future outlook as we seek to expand our core markets, diversify our business through new product introductions, and expand internationally."

Third Fiscal Quarter 2013 Results

Year-to-Date Performance

Business Highlights during the Third Quarter of Fiscal 2013

Fiscal Year 2013 Outlook

The Company is raising its revenue expectations for fiscal year 2013 financial performance. Total revenue is now expected to be in a range of $595 million to $600 million, an increase to the previous guidance range of $575 million to $585 million. This represents 20 percent to 21 percent growth over our prior fiscal year. The Company is also increasing its guidance for fiscal year 2013 diluted earnings per share to $1.65 to $1.67, up from the previous guidance of $1.55 to $1.58 per share. The new range represents 27 percent to 28 percent growth over fiscal year 2012 diluted EPS. These projections are forward looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release. The Company will provide further detail on its business outlook during the conference call it is holding today to discuss its fiscal 2013 third quarter financial results.

Share Repurchase Program

Between May 2010 and March 2013, the Company repurchased $525 million of its outstanding common stock. In February 2013, our Board of Directors authorized the Company to repurchase an additional $200 million of our outstanding common stock. As of March 31, 2013, there is approximately $175 million available to repurchase shares under this authorization. The Company is authorized to repurchase shares from time to time through open market transactions or privately negotiated transactions as determined by management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.

Conference Call and Webcast

View post:
Myriad Genetics Reports Third Quarter Fiscal Year 2013 Results

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today reported financial results for the first quarter ended March 31, 2013. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities, progress with its antibody-drug conjugate (ADC) pipeline and technology and upcoming milestones.

In 2013 we have continued to deliver on the ambitious goals we have set for ADCETRIS, our pipeline and our ADC technology, said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. We and our collaborator, Millennium: The Takeda Oncology Company, are bringing ADCETRIS to patients in need through approvals to date in the United States, Canada, European Union and Switzerland. In addition, across both corporate and investigator-sponsored studies, there are currently more than 20 ongoing ADCETRIS clinical trials, including four phase 3 studies. Seattle Genetics is also advancing several additional ADCs, including two programs planned for phase 1 trial initiations during 2013, while our collaborators continue to advance more than a dozen ADCs in clinical development.

Recent ADCETRIS Highlights

Other Recent Highlights

Upcoming Milestones

First Quarter Financial Results

Total revenues in the first quarter of 2013 were $57.3 million, compared to $48.2 million in the first quarter of 2012. First quarter 2013 revenues include ADCETRIS net product sales of $33.9 million and ADCETRIS royalty revenues of $2.4 million from international sales of ADCETRIS by Takeda/Millennium. Revenues also reflect amounts earned under the companys ADCETRIS and ADC collaborations totaling $21.0 million in the first quarter of 2013.

Research and development expenses for the first quarter of 2013 were $47.7 million, compared to $38.5 million for the first quarter of 2012. This planned increase in 2013 was primarily driven by ADCETRIS expenses, including clinical trials to explore potential additional uses of ADCETRIS and drug supply to Takeda/Millennium under the collaboration. Research and development expenses also include increased investment in the companys ADC pipeline programs. Selling, general and administrative expenses for the first quarter of 2013 were $21.9 million, compared to $22.2 million for the first quarter of 2012.

Under the ADCETRIS collaboration with Takeda/Millennium, development costs incurred by Seattle Genetics are included in research and development expense. Joint development costs are co-funded by Takeda/Millennium on a 50:50 basis. Net reimbursement funding received from Takeda/Millennium is recognized as revenue over the development period of the collaboration along with other development payments received, including the upfront payment and development milestone payments. Seattle Genetics co-funds development activities performed by Takeda/Millennium under the collaboration, which reduces the amount of reimbursement funding received from Takeda/Millennium.

More here:
Seattle Genetics Reports First Quarter 2013 Financial Results

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/lvclfm/gene_therapy) has announced the addition of Jain PharmaBiotech's new report "Gene Therapy - Technologies, Markets and Companies" to their offering.

Gene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state. Genes and DNA are now being introduced without the use of vectors and various techniques are being used to modify the function of genes in vivo without gene transfer. If one adds to this the cell therapy particularly with use of genetically modified cells, the scope of gene therapy becomes much broader. Gene therapy can now combined with antisense techniques such as RNA interference (RNAi), further increasing the therapeutic applications. This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy report written by him during the past decade including a textbook of gene therapy and a book on gene therapy companies. This report describes the setbacks of gene therapy and renewed interest in the topic

Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression.

Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included.

Research and development is in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of 2012, over 2030 clinical trials have been completed, are ongoing or have been approved worldwide.A breakdown of these trials is shown according to the areas of application.

The voluminous literature on gene therapy was reviewed and selected 750 references are appended in the bibliography.The references are constantly updated. The text is supplemented with 73 tables and 15 figures.

Profiles of 181 companies involved in developing gene therapy are presented along with 204 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade. These companies have been followed up since they were the topic of a book on gene therapy companies by the author of this report. John Wiley & Sons published the book in 2000 and from 2001 to 2003, updated versions of these companies (approximately 160 at mid-2003) were available on Wiley's web site. Since that free service was discontinued and the rights reverted to the author, this report remains the only authorized continuously updated version on gene therapy companies.

Benefits of this report

- Up-to-date on-stop information on gene therapy with 73 tables and 15 figures

Link:
Research and Markets: Gene Therapy - Technologies, Markets and Companies - Updated 2013 Report

Stem Cell Patient Treated With Adult Stem Cell Therapy

By: Shaun Scott

Read more:
Stem Cell Patient Treated With Adult Stem Cell Therapy - Video

Streak- Post Stem Cell Therapy Day 9
Looking good after moving sheep this morning, taking a morning walk through the woods, an evening walk to the river and generally running amuck with his cani...

By: Laura Hanley

Original post:
Streak- Post Stem Cell Therapy Day 9 - Video

New Delhi, May 5 (IANS) In a discovery that is paving the way for the diagnosis and treatment of a rare genetic disorder related to the brain's functioning, a team of researchers has identified the causative gene behind the disease, which delays development of motor activities in children.

The study was done on a four-year-old child from Punjab, and nine other children who were suffering from motor developmental delay. They could not walk and sit without support.

The team, led by Ryan Taft of the University of Queensland's Institute for Molecular Bioscience (IMB), comprised 16 researchers including I.C. Verma, director, Centre for Medical Genetics, Sir Ganga Ram Hospital and Monica Juneja, Department of Paediatrics, Maulana Azad Medical College.

The doctors used genome sequencing to determine that these children were suffering from a defect in a gene previously not associated with human disease.

"It has been found that mutations in a gene called DARS gene is responsible for causing inherited brain disorder called HBSL (Hypomyelination with Brain Stem and Spinal Cord Involvement and Leg Spasticity), which affects the motor development activities," a statement from the doctors said.

"We analysed the genome sequences of this child and his parents, using a method called whole genome sequencing and found that a mutation in the DARS gene was likely causing the disorder," Taft said.

"In collaboration with clinicians from India, Canada, Netherlands, Australia, and the US, we then examined the genomes of nine other children who appeared to be suffering from the same disease and the genomes of their parents, and confirmed that they all had mutations in the DARS gene," he said.

"This gene has never previously been associated with human disease and may not have been identified as the culprit using any other method," said Verma, who heads the department of genetics at Sir Ganga Ram Hospital.

Experts from Sir Ganga Ram Hospital and Maulana Azad Medical College, Delhi, India and IMB in Brisbane, Vrije Universiteit Medical Center in Amsterdam, Murdoch Children's Research Institute and The Royal Children's Hospital in Melbourne, and Children's National Medical Centre in Washington D.C came together for this research.

Verma elaborated: "They have named the disease HBSL because it causes Hypomyelination in the brain stem and spinal cord, leading to leg spasticity. Hypomyelination occurs when people do not have enough myelin, the substance that coats nerve fibres and enables the transmission of electrical impulses in the nervous system."

Read more:
Gene causing motor development disorder found

ST. ANTHONY At a clinic in rural Fremont County, innovative practices in veterinary medicine are fairly routine.

But many upper valley residents probably arent even aware of whats happening in a cluster of green roofed buildings west of U.S. Highway 20 in the Twin Groves area.

Dr. Richard Gearys Countryside Veterinary Clinic has international clients and patients. His expertise in bovine and equine reproduction is well known by cattle breeders and ranchers in Argentina and other countries.

After leaving a practice in his native Burley, he established his clinic in Fremont County in 1997. His expertise and client base has led to his becoming one of only three veterinarians in Idaho certified to collect embryos and prepare them for transfer internationally, to South America, the European Union and China.

He has many clients in the U.S. as well, including his neighbor, Brian Loosli, who operates a red Angus breeding ranch in the Ashton area. Ranchers with registered herds are his typical clients in the market for the embryo transfer process.

Most recently, he has branched out in his innovative practice and has learned how to collect stem cells and inject the activated cells to treat injured animals with some success.

It seems like a natural progression, since both processes require microscopic lab work.

Follow this link:
Innovative Fremont vet recognized for genetic research

Cancer Health Home>>Cancer>>Health news Provided by: RELAXNEWS Written by: Relaxnews May. 3, 2013

Some of the most devastating forms of cancer have genetic similarities even though they strike different body parts, according to new studies out Thursday.

The new research -- one study focused on a form of leukemia, in the New England Journal of Medicine, and a second on endometrial cancer, in Nature -- could offer a pathway to new, more effective treatments.

The new findings challenge the previous approach of classifying tumors based on the body part where they are first observed, and add fuel to the growing trend of differentiating tumors based on their genetic profile.

Thanks to that analysis, scientists had already found genetic relationships between certain forms of breast, lung, and colon cancers.

For example, one type of breast cancer presents genetic mutations very similar to the ones found in ovarian cancer, and colon cancers often have mutations found in breast cancer.

The researchers said around half of all lung cancers could respond to treatments used against other kinds of tumours.

The latest study found the most aggressive form of endometrial cancer, which affects the uterine lining, is similar to more grave forms of breast and ovarian cancer.

"The clinical and pathologic features of uterine serous carcinoma and high-grade serous ovarian carcinoma, or HGSOC, are quite similar," wrote the authors of the study published in Nature, which analyzed more than 370 tumors.

Likewise, "HGSOC shares many similar molecular features with basal-like breast carcinoma," added the team, which was directed by Douglas Levine of Memorial Sloan Kettering Cancer Center, in New York.

See more here:
U.S. studies find genetic links in aggressive cancers

GREENVILLE, S.C.--(BUSINESS WIRE)--

Thanks to an innovative Greenville Health System partnership with Selah Genomics, a new gene-based diagnostic test is paving the way for more precise and potentially far more effective cancer treatment at GHS.

This is the first time that this type of advanced genetic test has been developed, validated and employed in a clinical setting in South Carolina to empower oncologists to tailor specific treatment plans based on the particular molecular profile of each patients cancer.

Selahs PrecisionPath test, which was developed with clinical guidance from GHS oncologists, addresses the game-changing redefinition of the classification of cancer.

When it comes to treatment, one size does not fit all anymore, said Joe Stephenson, MD, medical director of GHS Institute for Translational Oncology Research (ITOR). Cancers have long been categorized and treated by the anatomic site of origin of the cancer for example, lung or breast but emerging science shows that we have exhausted what can be achieved with that approach.

Selahs Clinical Genomics Center at ITOR was founded to focus on the mutations, or alterations, in the genes that drive a persons cancer and to help clinicians, academic researchers and drug developers better target exactly what drugs would work best on an individuals specific cancer. This new type of genomic medicine uses molecular information about an individual as part of a physicians diagnostic or therapeutic decision-making.

So far, PrecisionPath has been performed on six common cancers: non-small-cell lung cancer, breast cancer, colon cancer, ovarian cancer, pancreatic cancer and melanoma. This powerful new capability, emerging from within the GHS Cancer Institute and ITOR, is the next logical step in GHS programmatic approach to personalizing cancer care.

This pilot program marks the start of routine molecular screening of cancer patients at GHS, said Dr. Larry Gluck, the medical director of the GHS Cancer Institute. Our community will enjoy accelerated access to promising new drugs that are usually only available at a handful of prominent academic cancer centers. It will be an enormous potential benefit for cancer patients from our entire region since they may now be matched to specific new medications being studied here or elsewhere.

PrecisionPath is built on Life Technologies' revolutionary new Ion Torrent Personal Genome Machine and is provided via its laboratories in the NEXT Innovation Center and at ITORs Innovation Zone. We are thrilled to leverage a powerful new generation of gene sequencers to enable focused clinical sequencing within GHS. And the pace of progress is accelerating, said Selah Genomics CEO Michael Bolick.

Using this in-house capability, GHS doctors are now developing treatment plans for cancer patients more quickly and more effectively. Selah is able to provide results to GHS doctors within a week, far faster than alternatives in the market. By specifically targeting the genetic makeup of each patients cancer, physicians can find a better treatment match, which may include a clinical trial, while also avoiding more toxic treatments and their damaging side effects. This test is also being used as a routine screening tool to facilitate enrollment on the next generation of targeted clinical trials.

Visit link:
GHS, ITOR and Selah to Transform Cancer Care with Genetic Testing

2013 Gartner 1to1 Media CRM Excellence Awards: AgReliant Genetics
Mobile CRM is helping the seed company be more agile in its sales process and led to more robust customer database.

By: 1to1Videos

See more here:
2013 Gartner

Soybean Genetics - Market Journal - May 3, 2013
Jim Orf, University of Minnesota Soybean Breeding and Genetics, measures the differences in soybean genetics between U.S. soybeans and South American soybeans.

By: marketjournal

More here:
Soybean Genetics - Market Journal - May 3, 2013 - Video

solving misconceptions and untruths about genetics
This is the final project that me and my wife did for our final project in Dr. Graur #39;s genetics class at the University of Houston Citations..... Dolly the s...

By: Kevin Sherman

View original post here:
solving misconceptions and untruths about genetics - Video

Let #39;s Play The Sims 3 - Perfect Genetics Challenge - Episode 2
This is a POSSIBLE LP that I am starting - I have recorded 3 episodes and will look at the responses (comments and likes) to determine if I will add this cha...

By: Llandros09

See original here:
Let's Play The Sims 3 - Perfect Genetics Challenge - Episode 2 - Video

By RTT News, May 06, 2013, 10:31:00 AM EDT

(RTTNews.com) - NewLink Genetics Corp. ( NLNK ) reported that its first-quarter of 2013 net loss widened to $7.9 million or $0.33 per share from $4.8 million or $0.23 per share in the first quarter of 2012.

Total grant revenues for the first quarter 2013 were $302,000 compared with $471,000 for the first quarter 2012.

Research and development expense for the first quarter 2013 was $6.3 million compared with $3.8 million for the first quarter 2012. The $2.5 million increase was primarily due to increased manufacturing and clinical trial expense from the same period in 2012.

General and administrative expense for the first quarter 2013 was $2.0 million compared with $1.5 million for the first quarter 2012. This increase was primarily due to increases in personnel related expenses.

The company said it expects to end 2013 with about $40 million in cash, cash equivalents and marketable securities.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.28 per share on revenues of $0.4 million for the quarter. Analysts' estimates typically exclude special items.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Follow this link:
NewLink Genetics Q1 Loss Widens - Quick Facts

LOS ANGELES, May 6, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its first quarter 2013 financial results and give an operational update in a press release to be issued before the market opens on Tuesday, May 14, 2013. The company will host a conference call that same day at 10:00 a.m. EDT to discuss its financial results.

CONFERENCE CALL DETAILS

To access the conference call by phone on May 14 at 10:00 a.m. EDT, dial (800) 537-0745 or (253) 237-1142 for international participants. A telephone replay will be available beginning approximately two hours after the call through May 16, 2013, and may be accessed by dialing (855) 859-2056 or (404) 537-3406. The conference passcode for both the live call and replay is 64250935.

To access the live and archived webcast of the conference call, go to the Investor Relations section of the Company's Web site at http://investor.responsegenetics.com. It is advised that participants connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX(R) products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Read the rest here:
Response Genetics, Inc. to Release First Quarter 2013 Financial Results and Host Conference Call on May 14, 2013

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGIX) (CGI) will present at the UBS Global Healthcare Conference on May 22, 2013 at 12:30 p.m. ET at the Sheraton New York. Panna Sharma, CEO and President, will provide a corporate overview.

The CGI presentation will be webcast live and can be accessed by visiting the investor relations section of the Companys website at http://ir.cancergenetics.com/events.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual patient. CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our reference laboratory is both CLIA certified and accredited by the College of American Pathologists. In addition, we have approvals and accreditations from the states of Florida, Maryland, New York, and New Jersey. The company has been built on a foundation of world-class scientific knowledge and IP in solid and hematologic cancers, as well as strong research collaborations with major cancer centers such as Cleveland Clinic and the National Cancer Institute.

CGIs dedicated staff takes pride in our specialized laboratory services, superior turnaround time, enhanced reporting, and ongoing research and development for new oncology tests. CGIs full-service cancer genetic practice and path to innovation with research makes for optimal patient care management. For further information, please seewww.cancergenetics.com.

The rest is here:
Cancer Genetics to Present at UBS Global Healthcare Conference

AMES, IA--(Marketwired - May 6, 2013) - NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapiesto improve treatment options for patients with cancer, today reported consolidated financial results for the first quarter of 2013.

"We are looking forward to completing patient accrual for our IMPRESS trial of algenpantucel-L for surgically resected pancreatic cancer. It was also encouraging to see additional clinical trials of both our HyperAcute and IDO product candidates advancing this past quarter," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink."In addition, NewLink presented preclinical results for our second IDO pathway inhibitor drug candidate, NLG919, at the American Association for Cancer Research annual meeting. Based on these data, we plan to initiate a clinical trial with NLG919 later this year, further expanding our clinical development programs."

First Quarter and Recent Accomplishments

Pipeline:

Corporate:

Upcoming Activities

NewLink expects to present at the following conferences:

First Quarter 2013 Financial Results

Financial Guidance

NewLink expects to end 2013 with about $40 million in cash, cash equivalents and marketable securities.

Excerpt from:
NewLink Genetics Corporation Reports First Quarter 2013 Financial Results

Virus to Help Heart Failure Patients
A virus can help heart failure patients. Doctors are hoping an engineered virus will help patients with heart failure by healing the damage caused by heart a...

By: GeoBeatsNews

See the original post:
Virus to Help Heart Failure Patients - Video

Untapped_healing: Maria Castro and Pedro Lowenstein at TEDxUofM
Maria Castro and Pedro Lowenstein are Professors of Neurosurgery and Cell and Developmental Biology at UofM. Maria #39;s research focuses on development of immun...

By: TEDxTalks

Originally posted here:
Untapped_healing: Maria Castro and Pedro Lowenstein at TEDxUofM - Video

Washington, May 4 (ANI): A researcher at Washington University School of Medicine in St. Louis has tried to identify a human gene that is more active after sleep deprivation by studying fruit flies.

For years, Paul Shaw, PhD, has used what he learns in fruit flies to look for markers of sleep loss in humans.

Shaw reverses the process in a new paper, taking what he finds in humans back to the flies and gaining new insight into humans as a result - identification of a human gene that is more active after sleep deprivation.

"I'm calling the approach cross-translational research," Shaw, associate professor of neurobiology said.

"Normally we go from model to human, but there's no reason why we can't take our studies from human to model and back again," he said.

Shaw and his colleagues plan to use the information they are gaining to create a panel of tests for sleep loss.

The tests may one day help assess a person's risk of falling asleep at the wheel of a car or in other dangerous contexts.

Scientists have known for years that sleep disorders and disruption raise blood serum levels of interleukin 6, an inflammatory immune compound.

Shaw showed that this change is also detectable in saliva samples from sleep-deprived rats and humans.

Based on this link, Shaw tested the activity of other immune proteins in humans to see if any changed after sleep loss.

Read more here:
Gene that becomes more active after sleep deprivation identified

Nine Eleven IS the LitmusTest
A seminal piece by Visible, leading to the obvious conclusion that, 9/11 is the litmus test without equal. http://www.smoking-mirrors.com/2008/02/911-is-litm...

By: Snordster

Original post:
Nine Eleven IS the LitmusTest - Video

Roy Morello, Ph.D. (Physiology and Biophysics and Genetics)
Roy Morello, Ph.D. (Physiology and Biophysics and Genetics) Web profile: In my laboratory we study the function of novel genes, in particular those involved ...

By: UAMSHealth

Read this article:
Roy Morello, Ph.D. (Physiology and Biophysics and Genetics) - Video

Bharat Book Pressents : Gene Therapy Technologies, Markets and Companies
For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/gene-therapy-technologies-markets-and-companies.html Benefit...

By: Deepa Kamath

Read more:
Bharat Book Pressents : Gene Therapy Technologies, Markets and Companies - Video

Olympic officials and scientific experts will meet in China next month to review the progress in developing a test for gene doping, the potential future of cheating in sports.

IOC medical commission chairman Arne Ljungqvist said researchers have made significant advances in devising a test, leaving officials hopeful a method can be approved soon for use at the Olympics and other events.

"Quite some progress has been made in terms of outlining the scientific basis for analysis of gene doping," Ljungqvist told The Associated Press. "We are moving. It's promising."

Up to 40 experts from around the world will meet in Beijing on June 5-6 to discuss recent findings and how to move forward in combatting the threat of athletes manipulating their genes to boost sports performance.

The meeting is being organized by the World Anti-Doping Agency in conjunction with China's national anti-doping agency. It will be the Olympic movement's fourth symposium on gene doping, following previous conferences in Cold Spring Harbor, New York, in 2002; Stockholm in 2005; and St. Petersburg, Russia, in 2008.

"There have been scientific studies which are quite promising," said Ljungqvist, also a WADA vice president. "We feel it's time to review this within the context of a small symposium of specialists."

Gene doping, which is prohibited by the IOC and WADA, involves transferring genes directly into human cells to blend into an athlete's own DNA to enhance muscle growth and increase strength or endurance. It is an illegal offshoot of gene therapy, which typically alters a person's DNA to fight diseases like muscular dystrophy and cystic fibrosis.

"We want to continue the momentum that we've got so we can get to a scenario where the detection methods can be approved," WADA director general David Howman told the AP. "It's close."

In 2010, two groups of scientists - one in Germany and a US-French research team - said they developed gene doping tests in what WADA described at the time as a major breakthrough. One was a blood test that would detect doping as far back as 56 days, while the other was for detecting genetic doping in muscles.

However, the tests have not been validated and hopes they could be used at the 2012 London Olympics were not realised.

Originally posted here:
IOC set to combat gene doping with new test